Max, I want to start with you. When we think about A. I.and drug discovery and the models that you and Iso labs are building for the layperson, what does that actually look like on a day to day basis for you and the team. So what we're doing at Isomorphic Labs, we're building this drug design engine. So you can think of this as a machine which is able to, you know, come up with new molecule designs for different disease areas, different indications, and even for different modalities, not just a single modal ...

The mission statement of Isomporhic Labs is to solve all disease. Where are we with in that mission. Well, I think we're making good progress.We're building a kind of general platform to help tackle the understanding, really, of biology and the chemistry that you need to buy into that biology. And I think if it works out, we should be able to tackle many, many diseases. How should we think about where the time frame sits then in terms of Iso labs discovering an AI drug and then getting it into clinical tria ...

>> YOU ARE WATCHING BLOOMBERG TECH EUROPE. COMING UP, A. I.DISCOVERY COULD BE THE NEXT FRONTIER OF MEDICINE TO SPEEDING UP DEVELOPMENT. THE TECHNOLOGY PROMISES PLENTY BUT WILL IT DELIVER. WE SPEAK EXCLUSIVELY TO DENNIS HASSABIS THE NOBLE LAUREATE, WHOSE LONDON-BASED ISOMORPHIC LABS HAS THE AMBITION 'TO SOLVE ALL DISEASE.' THE MAN RESPONSIBLE FOR ALL OF ALPHABET’S CORE A. I. WORK AS HEAD OF GOBBLE DEEPMIND IS SETTING THE BAR HIGH FOR ISOMOPHIC.>> THE KIND OF HOLY GRAIL IS TO TACKLE CANCER. BUT WE’VE DONE IT ...

Our CEO @demishassabis, Chief AI Officer @maxjaderberg, and Head of Medicinal Drug Design @_rebecca_paul were featured on the latest episode of Bloomberg Tech Europe (@technology) to share how we're leveraging frontier AI in groundbreaking ways to reimagine drug discovery and advance human healthFollow the link learn more about what Iso does and our progress towards solving all disease: https://t.co/udCOQflCFD ...

Discovering new medicines takes years and is marred by an astronomical failure rate. The Nobel Prize-winning head of Alphabet’s AI lab says the technology will soon trim that time to under a year https://t.co/yMO6xfKz86 ...

Absci Inc. ABSI on Thursday collaborated with Oracle Corporation’s ORCL Oracle Cloud Infrastructure (OCI) and AMD Inc. AMD to accelerate generative AI-driven drug discovery.Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.Also Read: Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA’s Decision To End Animal TestingWith OCI, Absci has been able to acceler ...

Absci (NASDAQ:ABSI) on Thursday announced a collaboration with Oracle Cloud Infrastructure (NYSE:ORCL) and AMD (NASDAQ:AMD) to accelerate its AI-driven drug discovery efforts. As part of the partnership, the Vancouver, Washington-based biotech will use Oracle’s (NYSE:ORCL) AI infrastructure and AMD’s ( ...

Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costsAUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastr ...

[Applause] Let's start with a small exercise. So to warm you up, I will have three questions to you. First of all, how many of you have used recently artificial intelligence.Okay. How many of you have used some kind of medicines le recently. Some of you.And how many of you know that AI can be used to find new drugs. Okay, great. Fantastic.So my name is Kamas Kazabel and today I will uncover like a hidden layers for you a world of medicines and how artificial intelligence can be used to find new drugs. But l ...

Company Overview - PreveCeutical Medical Inc. is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature-identical products [5] - The company has five research and development programs targeting diabetes, obesity, and other health issues, including dual gene therapy and non-addictive analgesic peptides [5] Leadership Appointment - BioGene Therapeutics Inc., a wholly owned subsidiary of PreveCeutical, appointed Dr. Francis Tavares as Chief Technology Officer effective August 19, 2025 [1][4] - Dr. Tavares has extensive experience in the biopharmaceutical industry, previously serving as President, CEO, and Founder of ChemoGenics BioPharma, and has a strong background in drug discovery and medicinal chemistry [2][3] Dr. Tavares' Contributions - Dr. Tavares has a PhD in Organic Chemistry and has led the development of significant drug candidates, including Trilaciclib and Lerociclib, demonstrating a successful track record in advancing drug candidates to clinical trials [3] - His appointment is expected to enhance BioGene's capabilities in drug discovery and product commercialization, benefiting both patients and investors [4] BioGene Therapeutics Inc. Overview - BioGene is focused on advancing innovative therapies in metabolic health and gene-based treatments, with a subsidiary in Australia that leverages a 43.5% R&D tax cashback incentive [6] - The company is engaged in research aimed at addressing the global diabetes and obesity crisis through gene therapy-based approaches [6]